Lyrica Use During Pregnancy: Safe?

Lyrica (pregabalin) is a drug used to treat epilepsy, fibromyalgia, neuropathic pain, and psychiatric disorders. While it is occasionally prescribed to pregnant women or those planning to conceive, there are concerns about its safety during pregnancy. Animal studies have shown increased incidences of fetal structural abnormalities and other developmental issues in offspring exposed to pregabalin. However, there is limited data on the effects of pregabalin in human pregnancy. Some studies have suggested an increased risk of congenital malformations, while others have found no significant association. Overall, pregabalin should be used during pregnancy only when clearly needed and when the benefits outweigh the risks. Patients should be advised of the potential risks and encouraged to use reliable contraception during treatment.

Lyrica (Pregabalin) is not recommended during pregnancy unless the benefit outweighs the risk

Pregabalin is approved by the US Food and Drug Administration (FDA) for the treatment of epilepsy, fibromyalgia, neuropathic pain, and certain types of seizures. It is also used off-label to treat psychiatric disorders, most commonly generalized anxiety disorder. While it is not as frequently used as other anti-epileptic drugs, some pregnant women do take pregabalin.

There have been a few studies investigating the effects of pregabalin on pregnancy. One small study found an increase in the risk of congenital malformations in children exposed to pregabalin during pregnancy, with a rate of 6.0% compared to 2.1% in the non-exposed group. Another larger study, using data from the US Medicaid Analytic eXtract (MAX) database, found that the risk of major congenital malformations was higher in infants exposed to pregabalin during the first trimester (5.9%) compared to those who were not (3.3%). However, after controlling for potential confounding variables, the risk decreased and the findings did not confirm the previous report of teratogenicity.

Despite these findings, it is important to note that there is still a possibility of a small effect, and the US FDA has not assigned a pregnancy category to pregabalin. Therefore, it is recommended that women of childbearing potential use reliable contraception during treatment and discuss the risks and benefits with their doctor if they are pregnant or planning to conceive.

Pregabalin is used to treat epilepsy, fibromyalgia, neuropathic pain, and psychiatric disorders

Pregabalin is an anticonvulsant that works by decreasing the number of pain signals sent out by damaged nerves in the body. It is used to treat epilepsy, fibromyalgia, neuropathic pain, and psychiatric disorders.

Pregabalin is available in capsule, oral solution, and extended-release tablet forms. It is usually taken two or three times a day with or without food. The dose is typically started low and gradually increased over the first week of treatment.

Pregabalin may cause side effects such as somnolence, dizziness, lack of coordination, and uncontrollable shaking or jerking. It may also cause serious side effects, including blurred vision, swelling of the eyes, mouth, or throat, muscle pain, difficulty breathing, and bluish-tinged skin, lips, or fingernails.

Pregabalin may not be safe for pregnant women, as it has been linked to decreased fertility and birth defects in animal studies. It may also cause dizziness and drowsiness, so patients should not drive or operate machinery until they know how the medication affects them.

There are no well-controlled studies of Pregabalin in pregnant women, but animal studies show increased fetal abnormalities

Pregabalin, marketed as Lyrica, is a drug used to treat epilepsy, fibromyalgia, neuropathic pain, and psychiatric disorders. While it is not frequently used, some pregnant women take pregabalin. However, there is limited research on the safety of pregabalin during pregnancy.

There is a lack of well-controlled studies examining the effects of pregabalin on pregnant women. Animal studies, on the other hand, have shown that pregabalin can cause increased fetal abnormalities and other developmental issues. In particular, rat and rabbit offspring exposed to pregabalin during organogenesis exhibited structural abnormalities, retarded ossification, and decreased body weight. Additionally, rat offspring exposed to pregabalin during gestation and lactation displayed growth retardation, nervous and reproductive system functional impairment, and neurobehavioral abnormalities in adulthood.

The potential risks of pregabalin exposure during pregnancy should be carefully considered and weighed against the benefits. Patients should be informed of the possible risks to the fetus, and alternative treatments should be considered if available. Furthermore, women of childbearing age should use reliable contraception while taking pregabalin.

While there is limited data on the effects of pregabalin during pregnancy, the available evidence suggests an increased risk of fetal abnormalities. This highlights the importance of further research to fully understand the potential risks associated with pregabalin use during pregnancy.

A small human study found an increase in congenital malformations in children exposed to Pregabalin in the first trimester

The study's results are consistent with those of a previous multicenter study from the European Teratology Information Services network, which reported an association between Pregabalin use during pregnancy and the risk of major congenital malformations in the fetus. The multicenter study found that 7 out of 116 infants (6%) exposed to Pregabalin during the first trimester had structural malformations, compared to 12 out of 580 (2.1%) in the reference group. The authors and editors of the study expressed concern about the potential risks of Pregabalin exposure during pregnancy and called for further independent studies to confirm their findings.

It is important to note that the studies mentioned above have their limitations and the results should be interpreted with caution. The small sample size in the multicenter study may have contributed to the possibility of random error, and residual confounding factors may also impact the results. Additionally, the studies did not find a definitive causal link between Pregabalin exposure and congenital malformations, but rather an association. Further research is needed to fully understand the potential risks of Pregabalin use during pregnancy.

Women of childbearing age should use reliable contraception during treatment

The US FDA has not assigned a pregnancy category for pregabalin, and there are no adequate and well-controlled studies in pregnant women. However, the AU TGA has assigned pregabalin a pregnancy category of B3, meaning that the drug has been taken by a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Nevertheless, due to the potential risk to a fetus, women who are pregnant or planning to become pregnant should consult their doctor about the risks and benefits of taking Lyrica.

Frequently asked questions